Metro Pharma

Metro International Biotech is a clinical-stage biotechnology company focused on developing small molecule therapies that enhance cellular metabolism and promote healthy aging. The company's primary focus is on modulating nicotinamide adenine dinucleotide (NAD+) levels, a critical coenzyme that declines with age and is linked to various degenerative diseases. Their lead candidate, MIB-626, is a proprietary, pharmaceutical-grade formulation of nicotinamide mononucleotide (NMN) currently being evaluated in multiple Phase 2 clinical trials for indications such as Alzheimer's disease, Friedreich's ataxia, and mitochondrial myopathy. Co-founded by renowned aging researcher Dr. David Sinclair, the company aims to translate breakthrough longevity science into regulated medical treatments.